研究概要
我们的模型为研究 HGSOC 中的腹膜癌病提供了有价值的平台,有望为开发新型治疗策略做出重要贡献。
中文摘要
**背景:**高级别浆液性卵巢癌(HGSOC)治疗面临重大挑战。晚期疾病常伴腹膜癌播散,其腹膜转移灶具有不同于原发肿瘤及其他转移部位的独特肿瘤微环境(TME)。理解细胞外基质(ECM)对肿瘤表型的关键影响,对开发有效新疗法至关重要。
**方法:**本研究利用猪去细胞化腹膜来源ECM支架(称为腹膜基质,PerMa),建立HGSOC腹膜转移的三维模型。
**结果:**研究显示,去细胞化处理保留了ECM分子的结构完整性和组成。比较分析发现,猪与人腹膜基质在结构、组成及力学特征上相似,说明猪模型具有模拟人体腹膜生理的转化研究价值。PerMa支持HGSOC细胞系在三维环境中生长。该模型可通过共聚焦成像和细胞体积定量,评估肿瘤对传统化疗及新型细胞免疫疗法的敏感性。
**解读:**该模型为研究HGSOC腹膜癌播散提供了有价值的平台,有望为开发新型治疗策略作出重要贡献。
**经费来源:**研究经费来自卑尔根大学、Helse Vest RHF(F-12183-D10616、779、911182、912035和912146)、Helse Bergen HF(240222)、挪威癌症协会(6833652和182735)、挪威研究理事会(250317、326300、223250、262652和295910)、Novo Nordisk基金会(NNF21OC0070381)、Kolbjørn Brambani癌症研究基金、美国国立卫生研究院(R01CA199646)及瑞典癌症协会(21 1888 Pj)。
展开英文摘要原文
BACKGROUND: High-grade serous ovarian carcinoma (HGSOC) presents a significant therapeutic challenge. Late-stage disease is frequently associated with peritoneal carcinomatosis. The peritoneal metastases exhibit a unique tumour microenvironment (TME) distinct from the primary tumours and other metastatic sites. Understanding the critical influence of the extracellular matrix (ECM) in shaping the tumour phenotype is essential for the development of effective new therapies.
METHODS: This study introduces a three-dimensional (3D) model of HGSOC peritoneal metastases using a porcine decellularised peritoneal-derived ECM scaffold, referred to as peritoneal matrix (PerMa).
FINDINGS: We show that the decellularisation maintains the structural integrity and composition of ECM molecules. Comparative analysis reveals structural, compositional, and mechanical similarities between porcine and human peritoneal matrices, underscoring the porcine model's translational relevance for modelling human peritoneum physiology. The PerMa supports the 3D growth of HGSOC cell lines. The model enables the assessment of sensitivity to traditional chemotherapy and novel cell-based immunotherapy through confocal imaging and quantification of cell volume.
INTERPRETATION: Our model offers a valuable platform for investigating peritoneal carcinomatosis in HGSOC, with the potential to contribute significantly to developing novel therapeutic approaches.
FUNDING: Financial support was provided by the University of Bergen, Helse Vest RHF (F-12183-D10616, 779, 911182, 912035, and 912146), Helse Bergen HF (240222), the Norwegian Cancer Society (6833652 and 182735), the Research Council of Norway grants (250317, 326300, 223250, 262652, and 295910), the Novo Nordisk Foundation (NNF21OC0070381), the Kolbj rn Brambani Legat for Kreftforskning, the National Institute of Health (R01CA199646) and the Swedish Cancer Society (21 1888 Pj).
论文信息
- 作者
- Gjerde CH、Kleinmanns K、Langer A、Ruiz de Garibay Ponce G、Rozmus E、Stangeland GN、Leitch C、Elnour R
- 第一作者单位
- Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Jonas Lies vei 87, 5021, Bergen, Norway; Department of Obstetrics and Gynecology, Haukeland University Hospital, Haukelandsbakken 15, 5021, Bergen, Norway. Electronic address: christiane.gjerde@uib.no.Norway
- 通讯作者单位
- Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Jonas Lies vei 87, 5021, Bergen, Norway; Centre for Pharmacy, Department of Clinical Science, University of Bergen, Jonas Lies vei 87, 5021, Bergen, Norway; K.G. Jebsen Center for Myeloid Blood Cancer, Department of Clinical Science, University of Bergen, Jonas Lies vei 87, 5021, Bergen, Norway; Department of Hematology, Haukeland University Hospital, Jonas Lies vei 83, 5021, Bergen, Norway. Electronic address: emmet.mc.cormack@uib.no.Norway
- 期刊
- EBioMedicine2026 Feb